# Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device

> **NCT01306357** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- Turner's Syndrome
- Human Growth Hormone Deficiency

## Interventions

- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT01306357
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306357, "Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01306357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*